Conference
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group
Abstract
BACKGROUND & AIMS: The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 weeks) in maintaining remission in 293 patients with Crohn's disease. Patients were stratified according to the method of induction of remission (medical or surgical).
METHODS: Patients were …
Authors
Sutherland L; Martin F; Bailey R; Fedorak R; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Volume
112
Pagination
pp. 1069-1077
Publisher
Elsevier
Publication Date
April 1997
DOI
10.1016/s0016-5085(97)70117-3
Conference proceedings
Gastroenterology
Issue
4
ISSN
0016-5085